Statements (140)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:biotechnology
gptkb:pharmaceuticals |
| gptkbp:acquisition |
gptkb:Zymeworks
gptkb:Aclaris_Therapeutics gptkb:Checkmate_Pharmaceuticals gptkb:Decibel_Therapeutics Astra Zeneca's rare disease unit |
| gptkbp:awards |
gptkb:Fortune_500
gptkb:Nobel_Prize_in_Physiology_or_Medicine_(2018) Best Places to Work multiple industry awards Top 100 Global Innovators |
| gptkbp:biologics_license_application |
approved for multiple products
|
| gptkbp:biotechnology_sector |
leading company in biotechnology sector
|
| gptkbp:ceo |
gptkb:George_Yancopoulos
gptkb:Leonard_Schleifer |
| gptkbp:clinical_trial |
gptkb:vaccine
ongoing Phase 1 thousands of participants Phase 2 Phase 3 collaborative research efforts funding for clinical trials multiple ongoing extensive clinical data global locations Dupixent for asthma high clinical trial success rate Eylea for diabetic retinopathy Libtayo for skin cancer |
| gptkbp:collaboration |
gptkb:Astra_Zeneca
gptkb:Bayer_AG gptkb:National_Institutes_of_Health gptkb:U._S._Department_of_Defense various academic institutions with academic institutions Regeneron Pharmaceuticals and Sanofi |
| gptkbp:collaborative_projects |
numerous collaborative projects
|
| gptkbp:community_engagement |
various initiatives
|
| gptkbp:community_health |
involved in global health initiatives
|
| gptkbp:community_support |
support for local communities
|
| gptkbp:cultural_diversity |
commitment to diversity and inclusion
|
| gptkbp:employees |
over 8,000
|
| gptkbp:financial_performance |
strong financial performance
|
| gptkbp:focus |
biopharmaceuticals
|
| gptkbp:founded |
gptkb:1988
|
| gptkbp:founded_by |
gptkb:George_Yancopoulos
gptkb:Leonard_Schleifer |
| gptkbp:founder |
gptkb:Leonard_Schleifer
|
| gptkbp:grants |
provides research grants
|
| gptkbp:has_advisory_board |
has a scientific advisory board
|
| gptkbp:has_research_center |
state-of-the-art research facilities
|
| gptkbp:head_of_state |
active business development efforts
|
| gptkbp:headcount |
significant growth in recent years
|
| gptkbp:headquarters |
gptkb:Tarrytown,_New_York,_USA
gptkb:Tarrytown,_New_York |
| gptkbp:healthcare |
gptkb:Dupixent
gptkb:Regen-Cov gptkb:Eylea commitment to patient access |
| https://www.w3.org/2000/01/rdf-schema#label |
Regeneron Pharmaceuticals
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:innovation |
focus on innovative therapies
|
| gptkbp:instruction_set |
diverse pipeline of therapies
|
| gptkbp:invention |
over 1,000
numerous patents granted |
| gptkbp:investment |
in research and development
strong investor relations team |
| gptkbp:investment_strategy |
strong stock performance
|
| gptkbp:ipo |
gptkb:2014
|
| gptkbp:leadership |
experienced leadership team
|
| gptkbp:market_cap |
over $60 billion
$50 billion (2023) over $60 billion (2023) |
| gptkbp:market_position |
global market presence
|
| gptkbp:marketing_strategy |
focused market strategy
|
| gptkbp:material |
engaged in stock buyback programs
|
| gptkbp:net_income |
over $3 billion (2022)
|
| gptkbp:notable_products |
gptkb:Repatha
gptkb:Dupixent gptkb:Eylea gptkb:Praluent gptkb:Zaltrap |
| gptkbp:number_of_employees |
over 8000
|
| gptkbp:operations |
operates globally
|
| gptkbp:partnership |
gptkb:Astra_Zeneca
gptkb:Sanofi gptkb:Bayer |
| gptkbp:partnerships |
partnerships with healthcare providers
with healthcare organizations |
| gptkbp:philanthropy |
gptkb:healthcare_access
gptkb:Regeneron_Foundation COVID-19 response education initiatives community support programs various health initiatives |
| gptkbp:product |
gptkb:Libtayo
gptkb:Dupixent gptkb:Regen-Cov gptkb:Eylea |
| gptkbp:products |
gptkb:Dupixent
gptkb:Regen-Cov gptkb:Eylea |
| gptkbp:publications |
numerous scientific publications
|
| gptkbp:regulatory_compliance |
strong regulatory affairs team
|
| gptkbp:research_areas |
oncology
infectious diseases immunology ophthalmology |
| gptkbp:research_focus |
gptkb:Oncology
eye diseases oncology genetic diseases monoclonal antibodies cardiovascular diseases infectious diseases immunology ophthalmology inflammatory diseases metabolic diseases genetic medicine |
| gptkbp:revenue |
$8.5 billion (2020)
$8.5 billion (2022) over $10 billion (2022) |
| gptkbp:side_effect |
significant impact on healthcare
|
| gptkbp:social_responsibility |
commitment to corporate social responsibility
|
| gptkbp:stock_symbol |
gptkb:REGN
|
| gptkbp:sustainability |
environmental initiatives
renewable energy use diversity and inclusion programs employee volunteerism water conservation efforts green building practices community engagement programs waste reduction programs |
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:training |
extensive employee training programs
|
| gptkbp:bfsParent |
gptkb:W3_C
|
| gptkbp:bfsLayer |
3
|